Company Overview and News
It is not often you get to call a high priestess dirty. But gathering grease and grime – with dirt so ingrained her marble had turned black – she must have been praying for a miracle as she stood in an disused gallery deep in the belly of the British Museum. If god works in mysterious ways, he answered the high priestess' call in the form of thousands of cotton wool tips and a very patient conservator.
Venessa Manzano (extreme right, in red) started the Filipino School of New York and New Jersey, which has students as young as 4-years-old to as old as 80. CONTRIBUTED
Arlington, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Rosetta Stone Inc. (NYSE: RST), a world leader in technology-based learning solutions, today announced that John Hass, President and Chief Executive Officer, and Tom Pierno, Chief Financial Officer, will be participating at upcoming September investor conferences as follows:
Arlington, VA, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rosetta Stone Inc. (NYSE: RST), a world leader in technology-based learning solutions, today welcomed Jerry Huang as Senior Vice President with responsibility over the Company’s Language international expansion strategy. In this role, Jerry will report to Matt Hulett, Rosetta Stone’s President of Language.
Rosetta Stone Inc. (NYSE:RST) Q2 2018 Results Earnings Conference Call August 2, 2018 5:00 PM ET
The following slide deck was published by Rosetta Stone Inc. in conjunction with their 2018 Q2 earnings call.
With the conversion of Consumer Language to SaaS model complete, Rosetta Stone is now fully subscription-based
Earlier this month a large, sealed sarcophagus was discovered in Alexandria, Egypt along with an alabaster head believed to represent the person inside. Since we live in the digital age, we didn’t have to wait days or weeks for the news to travel across around the world, and the public’s imagination was instantly captivated on social media. We learned that the sarcophagus was made of black granite, that it was large—8 feet by 4 feet by 5 feet—which may make it potentially the largest sarcophagus found—and that it appeared to have been untouched.
Investors in Rosetta Stone Inc. (RST - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $7.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
RST TPH NVR TRN
2018-07-23 investorplace - 2
If you’re looking for consistent market success, the best thing you can do is to expand your time horizon. Chasing flavors of the week could profit you in the immediate frame, but too often, an unexpected event can derail your position. However, by picking ideas from long-term stocks to buy, you improve your odds significantly.
RST PIXY JOBS ALB UPS BKD FDX CVNA W AMZN TSLA WELL KO MCD
2018-07-20 investorplace - 3
With the economy in full-speed-ahead recovery mode, tax cuts boosting earnings and regulation rolling back, this is a great time to be a publicly traded company. And there is no sector that is better able to reap this bountiful harvest better than smaller companies.
RST NDLS UBCP SSI DEST SMSI
Arlington, July 19, 2018 (GLOBE NEWSWIRE) -- Rosetta Stone to Report Second Quarter 2018 Results on August 2
What’s next is not so much a trade war or even a cold war as the dawn of an ice age in relations between the two countries.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to RST / Rosetta Stone, Inc. on message board site Silicon Investor.
as of ET